Eurofins Technologies has launched GSD NovaType Select kit to enable rapid detection of the emerging SARS-CoV-2 variant B.1.1.529 variant. Offered through Gold Standard Diagnostics Europe, the kit comprises a set of RT-PCR assays to identify mutations in the SARS-CoV-2 genome in around one hour. GSD NovaType Select P681H can distinguish between B.1.1.529 variant from the Delta variant. Furthermore, all positive samples for the P681H mutation should be processed using GSD NovaType Select T478K as well as K417N to further distinguish B.1.1.529 from other variants of concern.
Novacyt has reported that its genesig Covid-19 Real-Time PCR test obtained approval in the UK under the Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (CTDA) of the UK Health Security Agency. Introduced on 31 January last year, the genesig COVID-19 assay is one of the first commercially available Covid-19 tests. It targets the ORF1ab gene and can potentially detect all known variants as well as SARS-Cov2 mutations. So far, the test has assessed more than 4.5 million sequences.
QuantuMDx has reported that its Covid-19 tests are capable of detecting all known SARS-CoV-2 virus strains, including the new variant B.1.1.529. The company said that its assays for open polymerase chain reaction (PCR) platforms; rapid PCR device Q-POC; and its upcoming respiratory panel can identify the new variant. Q-POC can be deployed in various settings including hospitals, pharmacies, clinics and workplaces. The device and its first test, a SARS-CoV-2 detection assay, have received CE-IVD marked for usage within Europe.